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Abstract
Blood glucose level is regulated by multiple pancreatic hormones, which regulate
it by different pathways in normal and abnormal conditions by expressing or
suppressing multiple genes or molecular or cellular targets. Multiple synthetic drugs
and therapies are used to cure glucose regulatory problems, while many of them are
used to cure other health issues, which arise due to disturbance in blood glucose
regulations. Many new approaches are used for the development of phytochemical-
based drugs to cure blood glucose regulation problems, and many of the compounds
have been isolated and identified to cure insulin resistance or regulate beta cell
function or glucose absorption in the guts or GLP-1 homoeostasis or two/more
pathways (e.g., either cure hyperglycemia or raise insulin resistance or cure pan-
creatic beta cell regeneration or augmentation of GLP-1, production of islet cell,
production and increased insulin receptor signaling and insulin secretion or
decreased insulin tolerance or gluconeogenesis and insulin-mimetic action or pro-
duction of α-glucosidase and α-amylase inhibitor or conserve islet mass or activate
protein kinase A (PKA) and extracellular signal regulated kinases (ERK) or activate
AMPK and reduce insulin sensitivity or suppress α-glucosidase activity and activate
AMPK and downstream molecules or prevents cell death of pancreatic β-cell and
activates SIRT1 or lower blood glucose due to their insulin-like chemical structures
or decrease lipid peroxidation.
Keywords: genes, molecular and cellular targets, hormones, pathways
1. Introduction
Blood glucose is regulated by the pancreatic hormones alone or in combination
with other endocrine glands and all this is controlled by one or more gene or cellular
or molecular targets. If any problem occurs in the normal pathway(s), then multiple
drugs or therapies are used to cure it. Moreover with the emerging technologies,
multiple plant based formulations has been synthesized or in process to cure all
blood glucose regulation problems and their associated diseases.
2. Hormones for the regulation of blood glucose levels
2.1 Pancreas: an exocrine and endocrine organ
2.1.1 Location
It is located at the back of stomach, within left upper abdominal cavity.
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2.1.2 Parts
Its parts are head, body and tail. Majority of this secretory organ consists of:
a. Acinar/exocrine cells: Which secrete pancreatic juice (containing digestive
enzymes i.e. amylase, pancreatic lipase and trypsinogen) into main and
accessory pancreatic duct.
b. Endocrine cells: Which secrete pancreatic hormones directly in blood stream
(in endocrine way). These cells cluster together and form the so-called islets
of Langerhans (small, island-like structures within the exocrine pancreatic
tissue and accounts for only 1–2% of the entire organ) (Figure 1). These are
five different types of cells and release various hormones [1]:
i.Glucagon-producing α-cells: They are 15–20% of the total islet cells
and releases Glucagon to increase blood glucose levels.
ii.Amylin-, C-peptide- and insulin-producing β-cells: They are
65–80% of the total cells and produces insulin to decrease glucose.
iii. Pancreatic polypeptide (PP)-producing γ-cells: 3–5% of the total
islet cells, to regulate the exocrine and endocrine secretion activity of
the pancreas, is made of them.
iv. Somatostatin-producing δ-cells: Constitute 3–10% of the total cells
and releases Somatostatin which inhibits both, glucagon and insulin
release.
v.Ghrelin-producing ɛ-cells: Comprise <1% of the total islet cells.
Figure 1.
Anatomical organization of the pancreas.
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3. Pathways involved to regulate blood glucose levels in normal and
abnormal conditions
Pancreas maintains blood glucose levels within a very narrow range (4–6 MM)
through glucagon and insulin by their opposing and balanced actions by the phe-
nomenon of glucose homeostasis. During sleep/between meals/when blood glucose
levels are low/during prolonged fasting, α-cells release glucagon and promote
hepatic glycogenolysis. Along with this, glucagon do hepatic and renal gluconeo-
genesis and increase endogenous blood glucose levels. In elevated exogenous glu-
cose levels, after a meal, insulin secretion is stimulated from β-cells and after
docking to its receptor on muscle and adipose tissue, insulin enables insulin-
dependent uptake of glucose into tissues and lowers blood glucose levels by remov-
ing the exogenous glucose from the blood stream (Figure 2). Moreover insulin
enhances glycogenesis, lipogenesis and incorporation of amino acids into proteins;
thus it performs its anabolic action as compared to glucagon which is catabolic.
Along with pancreas, other organs also regulate blood glucose levels (Figure 3).
4. Genes, molecular and cellular targets to regulate blood glucose levels
in normal and abnormal conditions
4.1 Genes to regulate blood glucose levels
Genetics is identifying a whole new set of genes, proteins and pathways that are
related to diabetes and blood sugar control. Till now, scientist have identified a
genetic disorder in MafA (it controls the production of insulin in β-cells). Surpris-
ingly, this genetic defect was present in an unrelated family along with diabetic and
insulinoma family members. The link of this gene with a defect was detected for the
first time and a stable resultant mutant protein was found with a longer life in the cell,
and found to be significantly more abundant in β-cells than its normal version [2].
Figure 2.
Maintenance of blood glucose levels by glucagon and insulin.
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Gene on chromosome-2 {encodes glucose-6-phosphatase catalytic 2 (G6PC2)} is
linked with fasting glucose levels and is primarily expressed in pancreatic β-cells to
convert glucose-6-phosphate back to glucose. Its genetic variation may be respon-
sible for reduction in insulin secretion that increases glucose concentration. Chron-
ically elevated levels of glucose may be a precursor for type 2 diabetes [3].
13 new genetic variants has been discovered by an international research con-
sortium and these variants can manipulate blood glucose regulation, insulin resis-
tance and function of insulin-secreting β-cells in European descent populations, in
which 05 of the following newly discovered variants raised the risk of developing
type 2 diabetes:
i. SNPs in the region of ADCY5 which influence fasting and postprandial
glucose levels.
ii. FADS1 which is linked with fasting glucose as well as lipid traits.
Figure 3.
Maintenance of blood glucose levels by different organs (a) during well fed state (b) during post-prandial state.
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iii. Only one variant, near IGF1 which is associated with insulin resistance
iv. β-cell impairment, which may play a larger role in type 2 diabetes than
previously recognized
v. Environment which may contribute to insulin resistance more than it does to
insulin secretion.
By using high-density microarray analysis, more than 31,000 genes, linked with
pancreas, have been discovered and main aim was to find which gen(s) were most
sensitive to glucose and fatty acids particularly from the products of high fat and
sugar diets. It was found that TNFR5 gene had maximum compassion to glucose and
fatty acids and due to high levels of fat and sugar, beta cells are destroyed due to its
over expression. These findings suggested that people with type-II diabetes, pri-
marily with poor blood glucose management/who have not been diagnosed, are
more likely to over express this gene that leads to β cell damage. But blocking of
TNFR5 in beta-cells, especially when glucose and fatty acids consumption is high,
halted their obliteration which shows that reticence of TNFR5 activity could be a
promising treatment strategy against type 2 diabetes [4].
To identify genetic variants responsible for blood sugar control, a genome-wide
association study was done to find SNPs which could be correlated with Fasting
Plasma Glucose levels. It was found that most strongly associated SNP was rs560887
in initial sampling of 650 non-obese French people. Same SNP was correlated with
FPG levels in a secondary sample of 3400 same people, approximately 5000 Finns
and a group of 860 obese French children. When results of all studied samples were
combined, researchers found that each copy of T version of rs560887 leads to a
0.06 mmol/L reduction in FPG while rs560887 did not correlate with insulin levels
or BMI of subjects. Moreover even after a 9 year follow-up period in French sam-
ples, this SNP also could not correlate with the risk of type 2 diabetes. Moreover two
other SNPs; rs1260326 and rs1799884 (previously found to be associated with FPG)
were also found to be significantly associated with FPG levels in same study and it
was concluded that genes affected by these SNPs affect the threshold level of
glucose in the bloodstream and triggered secretion of insulin by pancreas. When
threshold will be higher, level of blood glucose increase even before insulin starts to
regulate it [5].
4.2 Molecular pathway for blood glucose regulation
4.2.1 Glucagon and GLP-1 receptors
These are class B-GPCRs which are important targets for drugs of type 2 diabe-
tes, obesity and blood glucose regulation problems. Structures of several class A-
GPCRs have been solved, but class B receptors have not been well studied because
of technical challenges. Their structures were identified and reported by four inter-
national research teams; NIDDK, NIGMS, FDA and NIDA. Structure of Glucagon
receptor helps to understand how different domains cooperate in modulating the
receptor function at molecular level. GLP-1 receptor, identified by cryo-electron
microscopy, examined structure of receptor in complex with GLP-1 and its coupled
G-protein while detailed structure of GLP-1 receptor, when bound by small mole-
cules (that affect receptor’s activity) has also been given and it is difficult to expect
the importance of GPCRs which are targeted by about half of all drugs. Structural
information about these receptors is crucial for further drug discovery efforts [6].
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Control of blood glucose depends heavily on G-protein-coupled receptors
(GPCRs) which can span cell membranes to communicate signals from the outside
to inside of cell and starts a cascade of reactions in cell when once activated by
binding of a substance which had made these receptors an important target for drug
development. When blood glucose drops after an overnight fast, pancreas releases
glucagon which binds a GPCR, glucagon receptor, on liver and muscle cells and
stimulates cells to release glucose in blood. Moreover glucagon-like peptide-1 (GLP-
1) hormone works by binding to another GPCR, GLP-1 receptor, on pancreatic cells.
After a meal, intestine produces GLP-1, which leads to the production of insulin
from pancreas to stimulate cells to pick glucose from blood [7].
4.2.2 Heterocyclic scaffolds
For many years, heterocyclic scaffolds were the basis of anti-diabetic chemo-
therapies as bioactive scaffolds and have been evaluated for their biological
response as inhibitors against their respective anti-diabetic molecular targets over
past 5 years (2012–2017). Results revealed a diverse target sets of these scaffolds
including protein tyrosine phosphatase 1 B (PTP1B), dipeptidyl peptidase-4 (DPP-
4), free fatty acid receptors 1 (FFAR1), G protein-coupled receptors (GPCR),
peroxisome proliferator activated receptor-γ (PPARγ), sodium glucose co-
transporter-2 (SGLT2), α-glucosidase, aldose reductase, glycogen phosphorylase
(GP), fructose-1,6-bisphosphatase (FBPase), glucagon receptor (GCGr) and phos-
phoenolpyruvate carboxykinase (PEPCK) [8].
4.2.3 Incretin and adipokines
In addition to other several even newer therapies in development, Incretin-
based therapies, like dipeptidyl peptidase- 4 (DPP- 4) inhibitor and glucagon like
peptide-1 (GLP-1) analogues/mimetic offer a new therapeutic means for the treat-
ment of T2DM. Moreover a great attention has been focused by many researchers
on a number of potential molecular targets in adipocytes e.g. adipokines [8].
4.3 Insulin secretion signaling pathway
4.3.1 Molecular pathways for the insulin secretion
In β-cells, main stimulus for insulin release increases blood glucose levels after a
meal. This blood glucose is taken up by facilitative glucose transporter GLUT2
(SLC2A2) on the surface of β-cells. Once inside the cell, glucose undergoes glycoly-
sis and an amplified ATP/ADP ratio and this distorted ratio leads to close ATP-
sensitive K+-channels (KATP-channels). While in non-stimulated circumstances,
these channels open to ensure the maintenance of resting potential by transporting
K+-ions down their concentration gradient out of the cell. Upon closure, succeeding
decrease in potency of externally moved K+-current elicits depolarization of mem-
brane, followed by opening of voltage-dependent Ca+-channels (VDCCs). Increase
in intracellular Ca+ concentrations ultimately triggers fusion of insulin-containing
granules with membrane and succeeding release of their content. Whole secretory
process is biphasic and 1st phase lasts for around 5 minutes after the glucose
stimulus with the release of majority of insulin while in 2nd phase, which is some-
what slower, the remaining insulin is released. This insulin is stored in large dense-
core vesicles which are recruited near plasma membrane immediately after stimu-
lation so that it should be readily available. Key molecules that mediate the fusion of
the insulin-containing large dense-core vesicles belong to the superfamily of the
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soluble N-ethylmaleimide-sensitive factor attachment protein (SNAP) receptor
proteins (SNAREs).which are:
i. Synaptosomal-associated protein of 25kDa (SNAP-25)
ii. Syntaxin-1 and synaptobrevin 2 (or vesicle-associated membrane protein
VAMP2)
Sec1/Munc18-like (SM) proteins, glucose vesicles form SNARE complex. To initiate
fusion, synaptobrevin 2, a vesicle (v-) SNARE fuses with the target (t-) SNAREs
syntaxin-1 and SNAP-25, which are located in the target cell membrane (Figure 4) [9].
Numerous SNARE isoforms [syntaxin-1, 3 and 4, SNAP-25 and -23,
synaptobrevins 2 and 3 (VAMP2 and 3)] are involved in glucose-stimulated insulin
secretion whereas VAMP 8 (a non-essential SNARE protein for glucose-stimulated
insulin secretion) has its role to regulate glucagon-like peptide-1-potentiated insulin
secretion. In addition to SNARE and SM proteins, a calcium sensor is required to
initiate membrane fusion. Synaptotagmins (highly expressed in neurons and endo-
crine cells) participated in Ca2+-dependent exocytosis processes. Seventeen
synaptotagmins (Syts 1–17) have been identified while only eight (Syt-1, 2, 3,
5, 6, 7, 9 and 10) are able to bind Ca2+ and form a complex with the
SNAREs to smooth the progress of and activate vesicle-membrane fusion process.
Only Syt-3, 5, 7, 8 and 9 are concerned with insulin exocytosis [10].
4.3.2 Mechanism of insulin action
Several proteins are disturbed in the insulin signaling pathways in different
conditions of insulin resistance, particularly obesity, type-II diabetes mellitus, met-
abolic syndrome, cardiovascular diseases, inflammatory disorders, and cancer [11].
4.3.2.1 Insulin receptor
It is tetramer protein, composed of 02 extracellular α- subunits and two trans
membrane β-subunits. α-subunits have a binding site to insulin while the β-subunits
contain an intrinsic tyrosine kinase activity towards intracellular side. Insulin
Figure 4.
Glucose-stimulated insulin release from a pancreatic β-cell.
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binding to α-subunit leads to conformational change and activation of β-subunit
which results in tyrosyl autophosphorylation of the insulin receptor. After being
activated and phosphorylated, several major and better characterized insulin sig-
naling intracellular docking proteins {Src homology collagen (SHC), associated
protein substrate (APS) and insulin receptor substrates- 1 & 2 (IRS-1 and IRS-2)}
binds to insulin receptor for tyrosyl phosphorylation. All these proteins activate
glucose uptake and metabolism, protein synthesis, gene expression, cell survival,
growth, development, and differentiation. IRS proteins are phosphorylated on var-
ious tyrosine residues of the C-terminal region and generate specific sites for bind-
ing of proteins containing Src homoly-2 (SH2) domains [phosphatidylinositol-3
kinase (PI-3 K), Nck, and Grb-2.
4.3.2.2 Pi-3 K
It is composed by a catalytic subunit (p110) and a regulatory subunit (p85) and
mediate metabolic effects of the insulin. Binding of p85 subunit to phosphorylated
tyrosine residues of IRS proteins activate catalytic activity of p110 subunit and
subsequent rise in the generation of phosphatidylinositol 3,4-bisphosphate (PIP2)
and phosphatidylinositol 3,4,5-trisphosphate (PIP3) content. Downstream proteins
from PI3K pathway figure out several serine/threonine kinases e.g.
phosphoinositide-dependent protein kinase-1 (PDK-1), protein kinase B (PKB/
Akt), protein kinase C (PKC), p70 S6 kinase (p70S6K) and glycogen synthase
kinase-3 (GSK-3). All these kinases are involved in translocation of glucose trans-
porter-4 (GLUT-4) from intracellular vesicles to plasma membrane, glycogen and
protein synthesis, antiapoptotic effects and gene expression (Figure 4).
4.3.2.3 Cbl
Signaling pathways which are involved in glucose uptake due to insulin induc-
tion starts with the recruitment of APS to activated insulin receptor and subsequent
association and tyrosine phosphorylation of Cbl which interacts with Cbl associated
protein (CAP) through an SH3 domain and with flotillin (a constituent of lipid raft,
through a sorbin domain). Complex CrkII/C3G then binds to the phosphorylated
tyrosine and residues of Cbl and activate C3G activity that exchanges GDP for GTP
of TC10 (a small G-protein that belongs to the Rho family). After being activated,
TC10 participates in GLUT-4 translocation (Figure 5) [12].
4.3.2.4 Mitogen-activated protein kinase (MAPK)
This cascade starts with
1.The association of Shc to insulin receptor
2.Binding of Grb-2 to Shc or to IRS-1
3.Formation of the Grb-2/SoS (Son of Seven less) in the plasma membrane.
This complex leads to the activation of c-Ras and raf, starting the MAPK cascade.
MAPK pathway is involved in insulin induced differentiation, cell growth, and
development, along with some metabolic effects e.g. glycogen synthesis and GLUT-
4 translocation to plasma membrane (Figure 4). However, this cascade is not
enough or even required to this later effect [13].
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4.3.3 Molecular basis of insulin resistance
It occurs when insulin-sensitive tissues (skeletal muscle, adipose tissue and
liver) cannot respond properly to hormones which cause several chronic diseases,
particularly those which are linked to obesity (type-II diabetes mellitus, metabolic
syndrome, dyslipidemias, cardiovascular diseases, cancer and neurodegenerative
diseases). However precise mechanisms of insulin resistance are not fully under-
stood. Following factor have been proposed to participate in its development;
4.3.3.1 Increased plasma-free fatty acid level
As free fatty acids are elevated in obesity and related illness, they are supposed
to be responsible for insulin action impairment but still complete mechanisms are
not known. More availability of long chain saturated fatty acids results leads to
insulin resistance in liver, skeletal muscle and adipose tissue. Various hypotheses
proposed to explain insulin resistance induced by saturated fatty acids [14] are;
i. Randle cycle
ii. Oxidative stress
iii. Modulation of gene transcription
Figure 5.
Summary of the main insulin signaling pathways. GLUT-1 and -4: Glucose transporter-1 and -4; Grb-2:
Growth receptor binding-2; GSK-3: Glycogen synthase kinase-3; IR: Insulin receptor; IRS-1 and -2: Insulin
receptor substrate-1 and -2; MAPK: Mitogen-activated protein kinase; PDK-1: Phosphoinositide-dependent
kinase-1; PIP2: Phosphatidyl-inositol diphosphate; PI3: Phosphatidyl-inositol triphosphate; P: Phosphate; PKC:
Protein kinase C; PP-1: Phosphoprotein phosphatase-1; p70S6K: Protein 70 S6 kinase; p90rsk: Protein 90
ribosomal S6 kinase; Shc: Src homology collagen; SHP-2: Phosphatase with Src homology 2 domain; SoS: Son of
Sevenless.
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iv. Accumulation of intracellular lipid derivatives (diacylglycerol and
ceramides)
v. Mitochondrial dysfunction
vi. Inflammation
4.3.3.2 Subclinical chronic inflammation
Chronic state of inflammation in insulin responsive tissues is major contributor
to insulin resistance in obesity and related diseases. However, precise mechanisms
as well as mediators involved in this interaction are not completely defined yet.
Intracellular redox balance is delicately synchronized process that includes multiple
generating pathways and degrading systems. Physiologically, ROS contribute in
essential biological responses but their accumulation causes oxidative stress condi-
tion because of their highly oxidant nature to oxidize multiple intracellular compo-
nents particularly membrane phospholipids, proteins, and DNA. In insulin
resistance, increased ROS production and/or decreased ROS degradation is
observed that leads to an oxidative stress condition and activation of signaling
pathways related to stress. Oxidative stress is also responsible for muscle disorders
and contributes to insulin resistance process. Transgenic mice expressing human
ubiquitin protein E3 ligase (a protein that binds and promotes degradation of
superoxide dismutase-1) leads to reduced superoxide degradation and as a result
increased oxidative stress in the form of atrophy and sclerosis [15].
4.3.3.3 Oxidative and nutritive stress
Activation of signaling pathways to stress is another reason of insulin resistance.
Several serine/threonine kinases activated by oxidative stress pathways (JNK, PKC,
GSK-3, NF-kB, and p38 MAPK) have been suggested to impair insulin signaling
pathways [16].
4.3.3.4 Altered expression of several genes and mitochondrial dysfunctioning
Expression of genes involved in lipid and glucose metabolism, insulin signaling,
inflammation, redox balance and mitochondrial function is modified in insulin sig-
naling, which shows that these processes participate in the pathophysiology of insulin
resistance. Disturbed mitochondrial function has been suggested to have a central
role in these alterations, since this organelle participates in all these processes [17].
5. Current scenario of drugs and therapies to cure blood glucose
regulation problems
5.1 Drugs
5.1.1 Drugs to manage type I and type II diabetes or its complications
Many of the drugs have a combination of effects. If a person needs two or more
treatments to manage glucose levels, insulin treatment may be necessary. Possible
treatments for type 1 diabetes include [18]:
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1.Metformin (Glucophage, Glumetza, others): It is generally 1st medication for
type-II diabetes and works by reducing gluconeogenesis in liver and improves
body’s sensitivity to insulin so that body utilizes insulin in more effective way.
2.Sulfonylureas: They help patients body to secrete more insulin. Its examples
are glyburide (DiaBeta, Glynase), glipizide (Glucotrol) and glimepiride
(Amaryl) and its possible side effects are low blood sugar and weight gain.
3.Meglitinides: Repaglinide (Prandin) and nateglinide (Starlix) works like
sulfonylureas by stimulation of pancreas to secrete more insulin but they are
faster acting with short duration of their effect in the body and have risk of
causing hypoglycemia and weight gain.
4.Thiazolidinediones: Along with Metformin, it include rosiglitazone
(Avandia) and pioglitazone (Actos). They make the body’s tissues more
sensitive to insulin but these drugs causes weight gain and increased risk of
heart failure and anemia that’s why, these medications generally aren’t 1st
choice treatments.
5.DPP-4 inhibitors: Sitagliptin (Januvia), saxagliptin (Onglyza) and linagliptin
(Tradjenta) are its different forms and help to lessen blood sugar levels but
tend to have very unassuming effect as they do not cause weight gain but may
cause joint pain and increase pancreatitis risk.
6.GLP-1 receptor agonists: These are injections to sluggish digestion and lower
blood sugar levels. They often cause weight loss and its possible side effects are
nausea and increased risk of pancreatitis. It includes Exenatide (Byetta,
Bydureon), liraglutide (Victoza) and semaglutide (Ozempic). Current
research has shown that liraglutide and semaglutide may reduce risk of heart
attack and stroke (in people at high risk).
7.SGLT2 inhibitors: They prevent kidneys from reabsorbing sugar into blood
and leads to its excretion via urine. It includes canagliflozin (Invokana),
dapagliflozin (Farxiga) and empagliflozin (Jardiance). They may reduce the
risk of heart attack and stroke in people with a high risk of these conditions
while its side effects may include vaginal yeast infections, urinary tract
infections, low blood pressure and a higher risk of diabetic ketoacidosis. Only
Canagliflozin in this drug class has been associated with increased risk of lower
limb amputation.
8.Insulin: People with type-II diabetes need insulin therapy. In past, insulin
therapy was used as a last option but today it’s often prescribed due to its
instant benefits. It’s possible side effects are low blood sugar (hypoglycemia)
and its different forms are:
a. Rapid-acting injections: They take their effect within 5–15 minutes but
last for a shorter time of 2–4 hours and include:
i. Insulin lispro (Humalog)
ii. Insulin aspart (NovoLog)
iii. Insulin glulisine (Apidra)
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b. Short-acting injections: Its effect starts between 30 minutes to 1 hour
but it last for 3–8 hours e.g.
i. Regular insulin (Humulin R and Novolin R)
c. Intermediate-acting injections: It is effective after 1–4 hours and last
for 12–18 hours. e.g.
i. Insulin isophane, also called NPH insulin (Humulin N and Novolin N)
d. Long-acting injections: They are effective after 1/2 hours and last for
between 14 and 24 hours. Its different forms are:
i. Insulin glargine (Toujeo)
ii. Insulin detemir (Levemir)
iii. Insulin degludec (Tresiba)
e. Premixed injections: These are combinations of the above types of
insulin and all takes effect from 5 minutes to 1 hour and last for 10–
24 hours and its different forms are:
i. Insulin lispro protamine and insulin lispro (Humalog Mix 50/50 and
Humalog Mix 75/25)
ii. Insulin aspart protamine and insulin aspart (NovoLog Mix 50/50 and
NovoLog Mix 70/30)
iii. NPH insulin and regular insulin (Humulin 70/30 andNovolin 70/30)
f. People can breathe in rapid-acting inhalable insulinwhich produces its
effects within 12–15 minutes and lasts for 2–3 hours e.g.
i. Insulin human powder (Afrezza)
9.Non-Inulin Injectables:
a. For Patients with Type-1 Diabetes: These drugs are common for type 1
diabetic patients and its different forms are:
i. Amylin analogs: Pramlintide (Symlin) which mimics another
hormone, amylin, that plays a role in glucose regulation.
ii. Glucagon which can reverse blood sugar levels when they fall too
low as a result of insulin treatment.
b. For patients with Type-II Diabetes:
i. Insulin: It can also manage high blood glucose levels in type-II
diabetes but doctors typically prescribe it only when other
treatments have not had the desired effect. Type-II diabetic pregnant
women may also use it for the reduction of disease effects on fetus
while for people with high blood glucose levels, in-spite of applying
12
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lifestyle measures to bring them down, doctors can prescribe non-
insulin drugs to lower blood glucose. These drugs are:
1.Sulfonylureas: They improve insulin secretion by the pancreas into
blood and people use following newer medicines most often because
of their less adverse effects. These are:
a. Glimepiride (Amaryl)
b. Glipizide (Glucotrol)
c. Glyburide (DiaBeta, Micronase, Glynase)
d. The older, less common sulfonylureas are:
1.Chlorpropamide (Diabinese)
2.Tolazamide (Tolinase)
3.Tolbutamide (Orinase)
Today these drugs are less prescribed than in the past as they can cause hypo-
glycemia, leading to other health issues:
i.Meglitinides: They improves insulin secretion and might also improve the
effectiveness of body to release insulin during meals. Its different forms are:
1.Nateglinide (Starlix)
2.Repaglinide (Prandin)
ii. Biguanides: They boost the effect of insulin, reduce the amount of glucose
from liver and increase uptake of blood glucose into cells.
iii.Metformin: It is the only licensed biguanide in the US and is available in the
form of Glucophage, Glucophage XR, Glumetza, Riomet, and Fortamet.
iv.Thiazolidinediones: They reduce the resistance of tissues to the effects of
insulin and are associated with serious side effects so they need monitoring
for potential safety issues. People with heart failure should not use these
medications. They include:
1.pioglitazone (Actos)
2.rosiglitazone (Avandia)
3.Alpha-glucosidase inhibitors
4.acarbose (Precose)
5.miglitol (Glyset)
6.Dipeptidyl peptidase inhibitors
13
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7.alogliptin (Nesina)
8. linagliptin (Tradjenta)
9.sitagliptin (Januvia)
10.saxagliptin (Onglyza)
v. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: They cause body to
release more glucose into the urine from the bloodstream and might also lead
to a modest amount of weight loss, which can be a benefit for type-II diabetic
patients. These include:
1.canagliflozin (Invokana)
2.dapagliflozin (Farxiga)
3.empagliflozin (Jardiance)
4.ertugliflozin (Steglatro)
vi. Incretin mimetics: The drugs that imitate incretin hormone and stimulate
insulin release after meals are:
1.exenatide (Byetta, Bydureon)
2. liraglutide (Victoza)
3.dulaglutide (Trulicity)
4. lixisenatide (Adlyxin)
5.semaglutide (Ozempic)
vii.Oral combination drugs: Drugs that are obtained after combination of some
of previous drugs include:
1.alogliptin and metformin (Kazano)
2.alogliptin and pioglitazone (Oseni)
3.glipizide and metformin (Metaglip)
4.glyburide and metformin (Glucovance)
5. linagliptin and metformin (Jentadueto)
6.pioglitazone and glimepiride (Duetact)
7.pioglitazone and metformin (Actoplus MET, Actoplus MET XR)
8.repaglinide and metformin (PrandiMet)
9.rosiglitazone and glimepiride (Avandaryl)
10.rosiglitazone and metformin (Avandamet)
14
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11.saxagliptin and metformin (Kombiglyze XR)
12.sitagliptin and metformin (Janumet and Janumet XR)
viii.Alternatives: U.S. Food andDrugAdministration has permitted ergot alkaloid,
bromocriptine (Cycloset) to treat type-II diabetes.Doctors donot oftenpropose/
set down this medication.Moreover people use bile acid sequestrants tomanage
cholesterol levels which can also help tomaintain steady blood sugar levels.
Alongwith these, only colesevelam (Welchol) is approved for type-II diabetes.
5.1.2 Drugs that may help to prevent the complications of diabetes.
5.1.2.1 ACE inhibitors or angiotensin-II receptor blockers
They are used to treat high blood pressure to prevent or manage kidney compli-
cations of diabetes.
5.1.2.2 Statins and aspirin
People can manage cardiovascular risks of diabetes (like heart disease and
stroke) by taking them to lower cholesterol levels at a dozen of once per day on
doctors recommendation.
5.1.2.3 Drug for weight loss
It is key part of diabetes management and prevention and doctors might suggest
medicines to cure it without effective lifestyle measures [19]. These drugs are
i. Lorcaserin (Belviq): It enhances the feeling of being packed after food and
help to treat diabetic obesity.
ii.Orlistat (Alli and Xenical): This drug decreases absorption of fat from diet
and also support weight loss.
iii. Phentermine and topiramate (Qsymia): It is a grouped drug and reduce
appetite to treat obesity.
5.1.3 Current guidelines at each person’s situation and best approach for the individual
There are many guide lines for each person’s health situation and each can
choose best one according to their health conditions [20] e.g.
i. For people with type 2 diabetes and atherosclerotic cardiovascular disease
(CVD), 2018 guidelines recommend following drugs as part of the
antihyperglycemic treatment:
a. Sodium-glucose cotransporter 2 inhibitors (SGLT2)
b. Glucagon-like peptide 1 receptor agonists (GLP1-RA)
ii. Type-II diabetic people with atherosclerotic CVD and heart failure or a high
risk of heart failure should be prescribed with:
a. Sodium-glucose cotransporter 2 inhibitors
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iii. To treat people with type-II diabetes and chronic kidney disease, doctors
urged to consider following guidelines to stop chronic kidney disease, CVD
or both, from getting worse.:
a. Sodium-glucose co transporter 2 inhibitor
b. Glucagon-like peptide 1 receptor agonist
5.2 Therapies
When medicines and lifestyle changes are not enough to manage diabetes, a less
common treatment can become an option. Other treatments include different sur-
gical procedures for treating type-I or type-II diabetes [21–25] which are as follows:
5.2.1. Bariatric surgery
It is also called weight-loss surgery or metabolic surgery and it help obese and
type-II diabetic patients to lose a large amount of weight and regain normal blood
glucose levels. Even some people with diabetes may no longer need their diabetes
medicine after it. Efficacy of this surgery can be checked by the variations in blood
glucose level, type of weight-loss surgery and the amount of lost weight by the
patients. Moreover it can also be monitored by the time occurrence of diabetes and on
duration of usage of insulin. Current research suggested that weight-loss surgery also
may help to improve blood glucose control in obese type-I diabetic people but still
scientists are finding long-term results of this in type-I and II diabetic patients [21].
5.2.2 Artificial pancreas
NIDDK has leading role to develop artificial pancreas technology. Artificial
pancreas replaces manual blood glucose levels by the shots or pumping of insulin.
Single system monitors blood glucose levels throughout the patient’s life and pro-
vide insulin or a combination of insulin and glucagon routinely. The system can also
be monitored remotely by parents or by medical staff. In 2016, FDA approved a
type of artificial pancreas system, called a hybrid closed-loop system which tested
blood glucose level after every 5 minutes throughout the day and night and auto-
matically provided right amount of insulin to body. But when person still needed
manual adjustment of insulin amount, pump delivered it at meal times. But artificial
pancreas make patient free from some of daily tasks which are needed to keep blood
glucose level steady or help to sleep through the night without need of wake and test
blood glucose or to take medicine. Hybrid closed loop system was available in the U.
S. in 2017. NIDDK has funded several important projects on different types of
artificial pancreas devices for the better help of Type- I diabetic people for proper
management of disease. These devices may also help type-II diabetic and gestational
diabetic people to cure their disease [22, 23].
5.2.3 Pancreatic islet transplantation
This is an experimental treatment for poorly controlled type-I diabetes as in this
condition immune system attacks islet cells. Pancreatic islet transplant replace
shattered islets with new ones to make and release insulin. In this process, islets are
donated from the pancreas of donor of pancreas and are transferred to a type 1
diabetic patient. As researchers are still doing work on pancreatic islet transplanta-
tion, so procedure is only accessible to volunteers of research studies [24, 25].
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6. New approaches to drug development and therapies, with a
particular focus on drug development by green synthesis to cure
blood glucose regulation problems
Bioactive molecules fromNatural products have been proved to improve insulin
resistance and its associated complications by suppressing inflammatory signaling path-
ways [26]. Medicinal plants cannot be obsolete and still play a prominent role in human
health care. Among natural sources, over 1200 plants have been claimed as antidiabetic
remedies. While over 400 plants along with its 700 recipes and compounds have been
scientifically evaluated for type-II diabetes. Metformin was developed on the basis of
Figure 6.
Mechanisms underlying herbal therapies using antidiabetic plants and phytocompounds. (a) Different types
of medicinal herbs can be classified based on their modes of action such as insulin resistance (type 1 herbs),
-cell function (type 2 herbs), and GLP-1 (type 3 herbs) and glucose (re) absorption (type 4 herbs),
(b) The selected.
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biguanide compound from an antidiabetic herb, French lilac and is now its a first-line
drug against type-II diabetes. Medicinal plants also contains a diverse bioactive com-
pounds and can have multiple actions on insulin action, insulin production, or both.
With a focus on scientific studies of selected glucose-lowering herbs, phyto compounds
Table 1.
Active compounds and biological actions of antidiabetic herbs.
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and their ability to target insulin resistance, cell function, incretin related pathways and
glucose (re)absorption (Figure 6a and b), multiple studies have been done.
While more than 400 plants and compounds have shown In-vitro and/or In-vivo
antidiabetic activities. Instead of listing each extract/compound, here, selected
chemicals from plants and/or their extracts with the ability to control blood glucose
levels as well as to modulate mechanisms involved in insulin resistance or cell
function or incretin-related pathways or glucose (re)absorption can be tabulated
(Table 1) along with chemical structure, antidiabetic activity and action in cells/
animal models and the results of administration of the plant extracts and com-
pounds to diabetic patients [27].
7. Conclusions
All hormones for the regulation of blood glucose levels along with their source
organ up to the level of cell have been discussed in first section of chapter. Then
different Pathways involved in regulating blood glucose levels in normal and
abnormal conditions has been explained. Genes, Molecular and cellular targets to
regulate blood glucose levels in normal and abnormal conditions has been discussed
with particular focus on molecular basis of insulin signaling pathways and this
pathway has been linked with Mechanism of Insulin Action and Molecular Basis of
Insulin Resistance which is may be due to fatty acids, inflammation, stress and
altered expression of several genes. Current scenario of Drugs and therapies to cure
blood glucose regulation problems for the management of type 1 and type 2 diabetes
has been explained. At the end New approaches to drug development and therapies
by green synthesis to have been mentioned.
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